Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Entacapone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Entacapone | DRUG | - |
Inclusion Criteria: * Attended the Phase IIb study * Able to fill out the patient diary Exclusion Criteria: * Serious heart, pulmonary, renal, hepatic or gastrointestinal disease * Dementia symptoms * Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may a...
Entacapone is used for Parkinson's Disease, specifically for patients experiencing end-of-dose wearing-off. It is a small molecule being developed as a treatment to address motor fluctuations associated with the condition.
Entacapone is being developed by Novartis AG, a global healthcare company. Novartis is listed on the stock exchange under the ticker symbol NVS.
Entacapone is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied to evaluate its effects in patients with Parkinson's Disease.
Entacapone has been studied in a completed Phase 2 clinical trial with the identifier NCT00237263. This trial was an extension study in patients with Parkinson's Disease with end-of-dose wearing-off, enrolling 285 participants in the United States.
Entacapone is a distinct drug entity. No alternative names have been established for this compound in the available clinical data, and it is referred to solely by its generic name, Entacapone.